Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Takes Step Back With Avelumab, Step Forward On CAR-T

Executive Summary

Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.

Advertisement

Related Content

Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer
Merck KGaA/Pfizer's Bavencio Set To Enter Europe's Crowded I-O Market
Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics
Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel